Request Sample Inquiry
Nanomedicine Market

Nanomedicine Market

Nanomedicine Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

149

Base Year:

2021

Date

Jun - 2022

Format:

PDF XLS PPT

Report Code:

VMR-1632

Segments Covered
  • By Modality Diagnostics, Treatment
  • By Application Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, Implants, Others
  • By Indication Clinical Oncology, Infectious Diseases, Clinical Cardiology, Orthopedics, Neurology, Urology, Ophthalmology, Immunology, Others
  • By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Forecast YearsForecast Years: 2022 - 2028
Historical YearsHistorical Years: 2016 - 2021
Revenue 2021Revenue 2021: USD 173.1 Billion
Revenue 2028Revenue 2028: USD 288.7 Billion
Revenue CAGRRevenue CAGR (2022 - 2028): 8.9%
Fastest Growing Region Fastest Growing Region (2022 - 2028) Asia Pacific
Largest Region Largest Region (2021): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics
  • Region Level Market Share
  • Import Export Analysis
  • Production Analysis
  • Others Request Customization Speak To Analyst
Nanomedicine Market Share

Global Nanomedicine Market

Nanomedicine Market- By Modality, Application, Indication and Region.

Market Synopsis:

The Global Nanomedicine Market is valued at USD 173.1 Billion in the year 2021 and is expected to reach a value of USD 288.7 Billion by the year 2028. The Global Market is anticipated to grow exhibiting a Compound Annual Growth Rate (CAGR) of 8.9% over the forecast period.

Nanomedicine Market Size, 2021 To 2028 (USD Billion)

Nanomedicine is the use of nanotechnology in the diagnosis and treatment of diseases. Nanomedicine is made up of nanoscale materials including biocompatible nanoparticles and nanorobots that can be used to diagnose, monitor, prevent, regulate, and treat diseases. Nanomedicine plays a critical role in the development of revolutionary medications with fewer side effects and greater efficacy than regular therapies due to novel features like size and form. The industry is still in its early stages, with various products in development.

The use of nanotechnology-based contrast reagents for diagnosis and monitoring of therapeutic effects on an unusually short timescale is also expected to fuel future growth. Demand is also expected to be influenced by the demand for biodegradable implants with extended lifespans that allow for tissue repair. Nanoparticles, nano-shells, nanotubes, and nanodevices are the different types of nanomedicine. The pandemic's breakout triggered a surge in demand for nanomedicines to treat a wide range of ailments. Nanomedicine applications opened up new avenues for the development of novel solutions for the prevention, diagnosis, and treatment of COVID-19 and other viral infections. As a result, the worldwide Nanomedicine Market has benefited.

An increase in nanorobot Research and Development (R&D) studies in this area, as well as major government and private sector investments in clinical trials, all contribute to market expansion. However, the industry is projected to be hampered by the lengthy clearance procedure and dangers connected with nanomedicines (environmental effect). Increased out-licensing of nano drugs and the expansion of healthcare facilities in emerging economies, on the other hand, are likely to provide the attractive potential for market expansion.

Furthermore, an increase in nanorobot Research and Development (R&D) studies in this area, as well as major government and private sector investments in clinical trials, all contribute to market expansion. However, the industry is projected to be hampered by the lengthy clearance procedure and dangers connected with nanomedicines (environmental effect). Increased out-licensing of nano drugs and the expansion of healthcare facilities in emerging economies, on the other hand, are likely to provide the attractive potential for market expansion. Making nanoparticles biocompatible is one of the most difficult issues for their usage in medicine. Nano capsules have demonstrated outstanding effectiveness in medication delivery in chemotherapy. Nanomedicine allows previously unattainable precision in both diagnostics and therapies. The Nanomedicine Market is likely to benefit from pipeline treatments being developed to target malignant tumors.

Market Segmentation:

The Nanomedicine Market is segmented on the basis of Modality, Application, and Indication. On the basis of Modality, the market is segmented into Diagnostics and Treatment. On the basis of Application, the market is segmented into Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, Implants, and Others. On the basis of Indication, the market is segmented into Clinical Oncology, Infectious Diseases, Clinical Cardiology, Orthopedics, Neurology, Urology, Ophthalmology, Immunology, and Others.

Below tree is interactive. You can click the nodes to get more information.

Based on Modality:

On the basis of Modality, the market is segmented into Diagnostics and Treatment. The treatment segment was the largest contributor to the global market in 2021 and is expected to remain dominant during the forecast period due to technological advancements in nanomedicines, increased adoption of nanomedicines, rising incidence rates of chronic diseases, and an increase in the number of advanced & effective product launches.

Based on Indication:

On the basis of Indication, the market is segmented into Clinical Oncology, Infectious Diseases, Clinical Cardiology, Orthopedics, Neurology, Urology, Ophthalmology, Immunology, and Others. The oncological disease segment is predicted to grow quickly in the next years as the global prevalence of cancer rises. Nanomedicine delivers sensitive cancer diagnosis and increased therapeutic efficacy with far fewer side effects than conventional medications. As Nanomedicine becomes more widely used in oncology, the market will expand.

North America is projected to acquire the largest market share during the year 2021

North America is projected to acquire the largest market share during the year 2021 with a share of 41.20%. The North American Nanomedicine industry is predicted to lead the Global Nanomedicine Market throughout the forecast period due to large government funding for Nanomedicine research in the United States. The region's rise is attributed to the increased availability of patented Nano-medicine products. The growing prevalence of chronic diseases around the world necessitates the development of technologically superior nanomedicines. Nanomedicines are growing in popularity due to the availability and use of nanomedical products such as nanorobots, DNA probes, monoclonal antibody-based immunoassays, nano-sensors, and nanoparticle-based imaging agents.

Furthermore, in North America, a favorable regulatory environment is a major driver of the Nanomedicine Market. The United States leads the region in Nanomedicine thanks to large government market research investment. Because of its excellent healthcare infrastructure and high cancer incidence, Nanomedicine is readily available in this region.

Competitive Landscape:

Key players operating in the Global Nanomedicine Market include- Abbott Laboratories, DiaSorin S.P.A., General Electric Company, Invitae Corporation, Johnson & Johnson, Leadient BioSciences Inc., Mallinckrodt PLC, Merck & Co. Inc. Pfizer Inc., Teva Pharmaceuticals Ltd. and others.

Segmentation of the Global Nanomedicine Market:

Parameter Details
Segments Covered
  • Modality (Diagnostics, Treatment)
  • Application (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, Implants, Others)
  • Indication (Clinical Oncology, Infectious Diseases, Clinical Cardiology, Orthopedics, Neurology, Urology, Ophthalmology, Immunology, Others)
  • Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
Regions & Countries Covered
  • North America - (U.S., Canada, Mexico)
  • Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
  • Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
  • Latin America - (Brazil, Argentina, Rest Of Latin America)
  • Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
Companies Covered
  • Abbott Laboratories
  • DiaSorin S.P.A.
  • General Electric Company
  • Invitae Corporation
  • Johnson & Johnson
  • Leadient BioSciences Inc.
  • Mallinckrodt PLC
  • Merck & Co. Inc. Pfizer Inc.
  • Teva Pharmaceuticals Ltd.
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis

Nanomedicine Market to Reach Valuation of USD 288.7 Billion by 2028 - Increasing Demand for Nanomedicine Market for Drug Delivery, Advantages of Nanomedicine in Various Healthcare Applications, and Growth in Need for Safe and Cost-Effective Therapies to Drive the Market Growth
From the period of 2022 to 2028, the Global Nanomedicine Market is expected to reach USD 288.7 Billion in terms of revenue, growing at a Compound Annual Growth Rate (CAGR) of 8.9%. Nanomaterials have unique physicochemical features that distinguish them from their bulk chemical counterparts becaus...
FAQ
Frequently Asked Question
  • The global Nanomedicine valued at USD 173.1 Billion in 2020 and is expected to reach USD 288.7 Billion in 2028 growing at a CAGR of 8.9%.

  • The prominent players in the market are Abbott Laboratories, DiaSorin S.P.A., General Electric Company, Invitae Corporation, Johnson & Johnson, Leadient BioSciences Inc., Mallinckrodt PLC, Merck & Co. Inc. Pfizer Inc., Teva Pharmaceuticals Ltd..

  • The market is project to grow at a CAGR of 8.9% between 2021 and 2028.

  • The driving factors of the Nanomedicine include

    • Rising level of government participation in R&D funding

  • North America was the leading regional segment of the Nanomedicine in 2020.